CD39 is identified as the vascular ATP diphosphohydrolase, which inhibits platelet aggregation and represents a potential target to prevent platelet activation associated with vascular inflammation.
No takes yet. Share an insight, caveat, or question.
May support CD39 as antithrombotic target in vascular inflammation; animal data leaves open human translation.
Kaczmarek et al. (1996) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: